Marinus Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Scott N. Braunstein
- Full Time Employees
- 165
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5 Radnor Corporate Center Radnor PA United States of America 19087
- IPO Date
- Jul 31, 2014
- CIK
- 0001267813
- Website
- marinuspharma.com
- Similar Companies
- Business
- Marinus Pharmaceuticals, Inc. (MRNS) develops and commercializes therapeutics for neuropsychiatric disorders, with a primary focus on treatments for rare and severe conditions such as status epilepticus and refractory status epilepticus. The company offers ganaxolone, an allopregnanolone neurosteroid that modulates GABA_A receptors for seizure control; ganaxolone oral suspension for cyclin-dependent kinase-like 5 deficiency disorder; and IV ganaxolone formulations for acute seizure management, alongside a pipeline including Ztalmy (ganaxolone) for pediatric epilepsy syndromes. Founded in 2003 and headquartered in Radnor, Pennsylvania, Marinus operates primarily in the United States and Europe, targeting patients with treatment-resistant epilepsies through partnerships with specialty pharmacies and healthcare providers in the biopharmaceutical sector. In the last 1-2 years, Marinus completed a strategic corporate restructuring in 2024, including workforce reductions and operational streamlining to extend cash runway amid clinical setbacks; announced positive topline results from the RAISE trial for IV ganaxolone in refractory status epilepticus in mid-2025, paving the way for regulatory filings; and secured a $100 million financing facility in late 2024 to support commercialization efforts. The company expanded its manufacturing capabilities through a new agreement with a contract development and manufacturing organization in 2025 and formed a collaboration with a European distributor for Ztalmy market access. These changes reflect Marinus' shift toward late-stage asset advancement and cost-efficient operations in the competitive CNS therapeutics market.
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
Pacific Defense Announces US Army CMFF Program Team